Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study

被引:176
作者
Mazza, M.
Capuano, A.
Bria, P.
Mazza, S.
机构
[1] Univ Cattolica Sacro Cuore, Dept Psychiat, I-00136 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dept Neurol, I-00136 Rome, Italy
关键词
Alzheimer; dementia; donepezil; EGb; 761; Ginkgo biloba; randomized controlled trial;
D O I
10.1111/j.1468-1331.2006.01409.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The Ginkgo biloba special extract EGb 761 seems to produce neuroprotective effects in neurodegenerative diseases of multifactorial origin. There is still debate about the efficacy of Ginkgo biloba special extract EGb 761 compared with second-generation cholinesterase inhibitors in the treatment of mild to moderate Alzheimer's dementia. Our aim is to assess the efficacy of the Ginkgo biloba special extract E.S. in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with donepezil and placebo. The trial was designed as a 24-week randomized, placebo-controlled, double-blind study. Patients aged 50-80 years, suffering from mild to moderate dementia, were allocated into one of the three treatments: Ginkgo biloba (160 mg daily dose), donepezil (5 mg daily dose), or placebo group. The degree of severity of dementia was assessed by the Syndrom Kurz test and the Mini-Mental State Examination. Clinical Global Impression score was recorded to assess the change in the patients' conditions and the therapeutic efficacy of tested medications. Our results confirm the clinical efficacy of Ginkgo biloba E.S. (Flavogin) in the dementia of the Alzheimer type, comparable with donepezil clinical efficacy. There are few published trials that have directly compared a cholinesterase inhibitor with Ginkgo for dementia. This study directly compares a cholinesterase inhibitor with Ginkgo biloba for dementia of the Alzheimer type and could be a valid contribution in this debate. Our study suggests that there is no evidence of relevant differences in the efficacy of EGb 761 and donepezil in the treatment of mild to moderate Alzheimer's dementia, so the use of both substances can be justified. In addition, this study contributes to establish the efficacy and tolerability of the Ginkgo biloba special extract E.S. in the dementia of the Alzheimer type with special respect to moderately severe stages.
引用
收藏
页码:981 / 985
页数:5
相关论文
共 16 条
[1]
Ahlemeyer B, 2003, PHARMACOPSYCHIATRY, V36, pS8
[2]
The ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid [J].
Bastianetto, S ;
Ramassamy, C ;
Doré, S ;
Christen, Y ;
Poirier, J ;
Quirion, R .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (06) :1882-1890
[3]
CEREBRAL BLOOD-FLOW IN DEMENTIA [J].
HACHINSKI, VC ;
ILIFF, LD ;
ZILHKA, E ;
DUBOULAY, GH ;
MCALLISTER, VL ;
MARSHALL, J ;
RUSSELL, RWR ;
SYMON, L .
ARCHIVES OF NEUROLOGY, 1975, 32 (09) :632-637
[4]
Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study [J].
Klinger, T ;
Ibach, B ;
Schoenknecht, P ;
Kamleiter, M ;
Silvere, G ;
Schroeder, J ;
Mielke, R .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (05) :723-732
[5]
Konowski S, 2003, PHARMACOPSYCHIATRY, V36, P297, DOI 10.1055/s-2003-45117
[6]
A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia [J].
LeBars, PL ;
Katz, MM ;
Berman, N ;
Itil, TM ;
Freedman, AM ;
Schatzberg, AF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (16) :1327-1332
[7]
Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type [J].
Maurer, K ;
Ihl, R ;
Dierks, T ;
Frolich, L .
JOURNAL OF PSYCHIATRIC RESEARCH, 1997, 31 (06) :645-655
[8]
Diagnostic and Statistical Manual of Mental Disorders [J].
Mittal, Vijay A. ;
Walker, Elaine F. .
PSYCHIATRY RESEARCH, 2011, 189 (01) :158-159
[9]
Can the cognitive enhancing effects of Ginkgo biloba be explained by its pharmacology? [J].
Nathan, P .
MEDICAL HYPOTHESES, 2000, 55 (06) :491-493
[10]
Nathan PJ, 2003, JAMA-J AM MED ASSOC, V289, P546, DOI 10.1001/jama.289.5.546-a